Matsuo S, Tsuchida S
Jpn J Antibiot. 1980 Oct;33(10):1129-37.
KW-1062 was administered intramuscularly at a daily dose of 360 mg for 5 days to 50 patients suffering from chronic complicated urinary tract infections. The following results were obtained. 1. Clinical response was excellent in 3 cases (6%), moderate in 23 (46%) and poor in 24 (48%); the overall effectiveness rate was 52%. 2. In bacteriological results, 58 (75.3%) out of 77 strains were eradicated and 19 strains (24.7%) persisted. P. aeruginosa was eradicated in 9 (52.9%) of 17 strains and Serratia in 10 (83.3%) of 12 strains. 3. The MIC levels of KW-1062 were slightly lower than those of gentamicin (GM) and almost the same as those of dibekacin (DKB). But against clinically isolated Serratia, KW-1062 was found to be more active than DKB. 4. As to side effects, this series showed no evidence of hepatic and renal dysfunction and hearing disturbance except a case which showed elevated GOT and GPT.
对50例慢性复杂性尿路感染患者，以每日360mg的剂量肌内注射KW - 1062，持续5天。得到以下结果：1. 临床反应中，3例（6%）为优，23例（46%）为中，24例（48%）为差；总有效率为52%。2. 细菌学结果显示，77株菌中有58株（75.3%）被清除，19株（24.7%）持续存在。17株铜绿假单胞菌中有9株（52.9%）被清除，12株沙雷氏菌中有10株（83.3%）被清除。3. KW - 1062的最低抑菌浓度水平略低于庆大霉素（GM），与地贝卡星（DKB）几乎相同。但对于临床分离的沙雷氏菌，发现KW - 1062比DKB更具活性。4. 关于副作用，除1例谷草转氨酶（GOT）和谷丙转氨酶（GPT）升高外，该组未显示肝肾功能障碍和听力障碍的证据。
